Pharnext, Ipsen in $126M Deal for Neuromuscular Compound June 17, 2009 By Nuala Moran Drug repositioning specialist Pharnext out-licensed its lead program in the chronic neuromuscular disease, Charcot-Marie-Tooth, to Ipsen SA in a deal with a value of at least €91 million ($US126.1 million). (BioWorld International)Read More
RSS